Cochrane · systematic review · CD012151
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
Hemmingsen, B, Sonne, DP, Metzendorf, MI, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
8
No studies
5
Included studies
NR
No studies 5 · 35.7%Ungraded 1 · 7.1%Very low 3 · 21.4%Low 0 · 0%Moderate 5 · 35.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings (sulphonylureas)
Population: people at risk for the development of type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 1 study · 274 participants | Very low Downgraded: imprecision, publication bias |
Incidence of type 2 diabetes mellitus Measured as 2 consecutive fasting blood glucose values ≥ 6.1 mmol/L (NANSY 2011b) or no definition provided (Eriksson 2006) | RR 0.75 [0.54, 1.04] | 2 studies · 307 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Serious adverse events | no estimate extracted | NR | No studies |
Cardiovascular mortality | no estimate extracted | 1 study · 274 participants | Very low Downgraded: imprecision, publication bias |
Non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure | no estimate extracted | NR | No studies |
Health‐related quality of life | no estimate extracted | NR | No studies |
Socioeconomic effects | no estimate extracted | NR | No studies |
Summary of findings (meglitinide analogues)
Population: people at risk for the development of type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | no estimate extracted | 1 study · 9306 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Incidence of type 2 diabetes mellitus Defined as: fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or a 2‐hour blood glucose after a glucose‐load test ≥ 11.1 mmol/L (200 mg/dL) or by an adjudication committeeb | no estimate extracted | 1 study · 9306 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Serious adverse events | no estimate extracted | 1 study · 9306 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Cardiovascular mortality | no estimate extracted | 1 study · 9306 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
(a) Non‐fatal myocardial infarction (b) Non‐fatal stroke (c) Congestive heart failure | no estimate extracted | 1 study · 9306 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Health‐related quality of life | no estimate extracted | NR | No studies |
Socioeconomic effects | no estimate extracted | 1 study · 9306 participants | Ungraded |